taxusin: RN given for (3S-(3alpha,4aalpha,6beta,8alpha,11beta,12alpha,12abeta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
taxusin : A taxane diterpenoid that is taxa-4(20),11-diene in which the 5alpha, 9alpha, 10beta and 13alpha hydrogens have been replaced by acetoxy groups. It is a prominent secondary metabolite of yew heartwood. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 167825 |
| CHEMBL ID | 368741 |
| CHEBI ID | 63664 |
| SCHEMBL ID | 6017679 |
| MeSH ID | M0279283 |
| Synonym |
|---|
| MLS000728577 |
| smr000445558 |
| taxusin |
| 6,10-methanobenzocyclodecene-3,8,11,12-tetrol, 1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-9,12a,13,13-tetramethyl-4-methylene-, tetraacetate, (4as-(4aalpha,6alpha,9beta,12abeta))- |
| 19605-80-2 |
| CHEMBL368741 |
| chebi:63664 , |
| NCGC00247553-01 |
| C20152 |
| HMS2214M17 |
| vhs5792rp7 , |
| unii-vhs5792rp7 |
| (5alpha,9alpha,10beta,13alpha)-taxa-4(20),11-diene-5,9,10,13-tetrayl tetraacetate |
| taxa-4(20),11-diene-5alpha,9alpha,10beta,13alpha-tetrayl tetraacetate |
| (+)-taxusin |
| SCHEMBL6017679 |
| [(1r,3r,5s,8r,9r,10r,13s)-9,10,13-triacetyloxy-8,12,15,15-tetramethyl-4-methylidene-5-tricyclo[9.3.1.03,8]pentadec-11-enyl] acetate |
| DTXSID90941377 |
| Q15427894 |
| (3s,4ar,6r,8s,11r,12r,12ar)-9,12a,13,13-tetramethyl-4-methylidene-1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-6,10-methanobenzo[10]annulene-3,8,11,12-tetrayl tetraacetate |
| 6,10-methanobenzocyclodecene-3,8,11,12-tetrol, 1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-9,12a,13,13-tetramethyl-4-methylene-, tetraacetate, (3s-(3.alpha.,4a.alpha.,6.beta.,8.alpha.,11.beta.,12.alpha.,12a.beta.))- |
| 6,10-methanobenzocyclodecene-3,8,11,12-tetrol, 1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-9,12a,13,13-tetramethyl-4-methylene-, tetraacetate, (3s,4ar,6r,8s,11r,12r,12ar)- |
| taxa-4(20),11-diene-5.alpha.,9.alpha.,10.beta.,13.alpha.-tetrol, tetraacetate |
| 6,10-methanobenzocyclodecene-3,8,11,12-tetrol, 1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-9,12a,13,13-tetramethyl-4-methylene-, 3,8,11,12-tetraacetate, (3s,4ar,6r,8s,11r,12r,12ar)- |
| taxusin, (+)- |
| (3beta,5beta,8alpha,9beta,10alpha,13beta)-5,10,13-tris(acetyloxy)taxa-4(20),11-dien-9-yl acetate |
| AKOS040763669 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| taxane diterpenoid | |
| acetate ester | Any carboxylic ester where the carboxylic acid component is acetic acid. |
| carbotricyclic compound | A carbopolyclic compound comprising of three carbocyclic rings. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| 2u03B1,7u03B2-dihydroxylation of taxusin | 2 | 3 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 15.8489 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 35.4813 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 24.8446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 15.8489 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 2.5119 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 2.5929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID361438 | Antiproliferative activity against mouse Colon 26-L5 cells by MTT assay | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | Three new C-14 oxygenated taxanes from the wood of Taxus yunnanensis. |
| AID377773 | Reversal of multidrug resistance in human 2780AD cells assessed as [3H]vincristine accumulation at 10 ug/mL after 2 hrs relative to control | 2005 | Journal of natural products, Apr, Volume: 68, Issue:4 | Taxoids and abietanes from callus cultures of Taxus cuspidata. |
| AID377775 | Reversal of multidrug resistance in human 2780AD cells assessed as [3H]vincristine accumulation at 1 ug/mL after 2 hrs relative to verapamil | 2005 | Journal of natural products, Apr, Volume: 68, Issue:4 | Taxoids and abietanes from callus cultures of Taxus cuspidata. |
| AID361437 | Antiproliferative activity against human HT1080 cells by MTT assay | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | Three new C-14 oxygenated taxanes from the wood of Taxus yunnanensis. |
| AID377772 | Reversal of multidrug resistance in human 2780AD cells assessed as [3H]vincristine accumulation at 1 ug/mL after 2 hrs relative to control | 2005 | Journal of natural products, Apr, Volume: 68, Issue:4 | Taxoids and abietanes from callus cultures of Taxus cuspidata. |
| AID377774 | Reversal of multidrug resistance in human 2780AD cells assessed as [3H]vincristine accumulation at 0.1 ug/mL after 2 hrs relative to verapamil | 2005 | Journal of natural products, Apr, Volume: 68, Issue:4 | Taxoids and abietanes from callus cultures of Taxus cuspidata. |
| AID377776 | Reversal of multidrug resistance in human 2780AD cells assessed as [3H]vincristine accumulation at 10 ug/mL after 2 hrs relative to verapamil | 2005 | Journal of natural products, Apr, Volume: 68, Issue:4 | Taxoids and abietanes from callus cultures of Taxus cuspidata. |
| AID377771 | Reversal of multidrug resistance in human 2780AD cells assessed as [3H]vincristine accumulation at 0.1 ug/mL after 2 hrs relative to control | 2005 | Journal of natural products, Apr, Volume: 68, Issue:4 | Taxoids and abietanes from callus cultures of Taxus cuspidata. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||